Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibalizumab - TaiMed Biologics

Next Previous
X
Search
Drug Profile

Ibalizumab - TaiMed Biologics

Alternative Names: Hu1A8; Hu5A8; Ibalizumab-uiyk; TMB-355; TNX-355; Trogarzo

Latest Information Update: 28 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer TaiMed Biologics; Theratechnologies
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • No development reported HIV-2 infections

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in HIV-2-infections in France (Parenteral)
  • 18 Mar 2024 Ibalizumab Commercialized to AcedrA BioPharmaceuticals in the Middle East and North Africa Region
  • 27 Feb 2024 Theratechnologies receives a refusal to file letter from the FDA for ibalizumab (Trogarzo®) in HIV-1 infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top